Touko Inao

Kumamoto, Japan

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 14 publications

Different sensitivities of senescent breast cancer cells to immune cell-mediated cytotoxicity.

Different sensitivities of senescent breast cancer cells to immune cell-mediated cytotoxicity.

Journal: Cancer science

Published: April 15, 2019

Associations in tumor infiltrating lymphocytes between clinicopathological factors and clinical outcomes in estrogen receptor-positive/human epidermal growth factor receptor type 2 negative breast cancer.

Associations in tumor infiltrating lymphocytes between clinicopathological factors and clinical outcomes in estrogen receptor-positive/human epidermal growth factor receptor type 2 negative breast cancer.

Journal: Oncology letters

Published: June 17, 2018

Bcl-2 inhibition sensitizes triple-negative human breast cancer cells to doxorubicin.

Bcl-2 inhibition sensitizes triple-negative human breast cancer cells to doxorubicin.

Journal: Oncotarget

Published: March 20, 2018

Erratum to: Post-relapse survival in patients with the early and late distant recurrence in estrogen receptor-positive HER2-negative breast cancer.

Erratum to: Post-relapse survival in patients with the early and late distant recurrence in estrogen receptor-positive HER2-negative breast cancer.

Journal: Breast cancer (Tokyo, Japan)

Published: April 06, 2017

Clinical features of lenvatinib treatment in elderly patients with advanced thyroid cancer.

Clinical features of lenvatinib treatment in elderly patients with advanced thyroid cancer.

Journal: Molecular and clinical oncology

Published: October 13, 2016

Post-relapse survival in patients with the early and late distant recurrence in estrogen receptor-positive HER2-negative breast cancer.

Post-relapse survival in patients with the early and late distant recurrence in estrogen receptor-positive HER2-negative breast cancer.

Journal: Breast cancer (Tokyo, Japan)

Published: June 01, 2016

Differences in expression of the cancer stem cell marker aldehyde dehydrogenase 1 among estrogen receptor-positive/human epidermal growth factor receptor type 2-negative breast cancer cases with early, late, and no recurrence.

Differences in expression of the cancer stem cell marker aldehyde dehydrogenase 1 among estrogen receptor-positive/human epidermal growth factor receptor type 2-negative breast cancer cases with early, late, and no recurrence.

Journal: Breast cancer research : BCR

Published: January 01, 2016

Fibroblast growth factor receptor-1 protein expression is associated with prognosis in estrogen receptor-positive/human epidermal growth factor receptor-2-negative primary breast cancer.

Fibroblast growth factor receptor-1 protein expression is associated with prognosis in estrogen receptor-positive/human epidermal growth factor receptor-2-negative primary breast cancer.

Journal: Cancer science

Published: November 12, 2015

Clinicopathological factors predicting early and late distant recurrence in estrogen receptor-positive, HER2-negative breast cancer.

Clinicopathological factors predicting early and late distant recurrence in estrogen receptor-positive, HER2-negative breast cancer.

Journal: Breast cancer (Tokyo, Japan)

Published: August 25, 2015

Prediction of sentinel lymph node status using single-photon emission computed tomography (SPECT)/computed tomography (CT) imaging of breast cancer.

Prediction of sentinel lymph node status using single-photon emission computed tomography (SPECT)/computed tomography (CT) imaging of breast cancer.

Journal: Surgery today

Published: May 19, 2014

A case of estrogen receptor-positive metastatic breast cancer in a postmenopausal woman treated with ethinyl estradiol

A case of estrogen receptor-positive metastatic breast cancer in a postmenopausal woman treated with ethinyl estradiol

Journal: Gan to kagaku ryoho. Cancer & chemotherapy

Published: December 17, 2013

Ethinylestradiol is beneficial for postmenopausal patients with heavily pre-treated metastatic breast cancer after prior aromatase inhibitor treatment: a prospective study.

Ethinylestradiol is beneficial for postmenopausal patients with heavily pre-treated metastatic breast cancer after prior aromatase inhibitor treatment: a prospective study.

Journal: British journal of cancer

Published: May 13, 2013

Showing 1-12 of 14

Last Updated: 09/26/2026